Table 3.

Potential biomarkers useful for the treatment with anti-CTLA-4

Increase in ALC (33–35)
Increased in circulating CD4+ICOShigh T cells (35–40)
Baseline level of Ki67+EOMES+CD8+ T Cells (47)
High expression of FOXP3 and indoleamine 2,3-dioxygenase at baseline and an increase from baseline in TILs in tumor biopsies (35)
Decrease in circulating Tregs (41)
Decrease of LDH level (41)
Lower pretreatment level of circulating MDSC (43)